title: How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).
abstract: Indolent systemic mastocytosis (SM) patients have a varied clinical presentation, ranging from predominantly cutaneous symptoms to recurrent systemic symptoms (eg, flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and potentially life threatening (anaphylaxis). Mastocytosis patients without skin involvement pose a diagnostic challenge; a high index of suspicion is needed in those with mast cell-degranulation symptoms, including anaphylaxis following Hymenoptera stings or other triggers. Modern-era molecular and flow-cytometric diagnostic methods are very sensitive and can detect minimal involvement of bone marrow with atypical/clonal mast cells; in some cases, full diagnostic criteria for SM are not fulfilled. An important aspect of treatment is avoidance of known symptom triggers; other treatment principles include a stepwise escalation of antimediator therapies and consideration of cytoreductive therapies for those with treatment-refractory symptoms. The perioperative management of mastocytosis patients is nontrivial; a multidisciplinary preoperative assessment, adequate premedications, and close intra- and postoperative monitoring are critical. Smoldering mastocytosis is a variant with high systemic mast cell burden. While its clinical course can be variable, there is greater potential need for cytoreductive therapies (eg, interferon-alpha, cladribine) in this setting. A systematic approach to the diagnosis and treatment of indolent SM using a case-based approach of representative clinical scenarios is presented here.
authors: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA. pardanani.animesh@mayo.edu
authors: Animesh
authors: A
authors: Pardanani
mesh_terms: D000707:Anaphylaxis / Q000150:complications / Q000628:therapy; D001847:Bone Diseases / Q000150:complications / Q000628:therapy; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000628:therapy; D008297:Male; D008407:Mast Cells / Q000378:metabolism / Q000473:pathology*; D008415:Mastocytosis / Q000150:complications / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D034721:Mastocytosis, Systemic / Q000150:complications / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D012867:Skin / Q000378:metabolism / Q000473:pathology*
chemical_list: D019009:Proto-Oncogene Proteins c-kit